Cancer Biomarkers Market by Type, Technology and Application – Forecast to 2022

According to research report the global cancer biomarkers market
is projected to reach USD 20.48 billion by 2022 from USD 11.53 billion
in 2017, at a CAGR of 12.2%. Cancer biomarkers are substances or
processes that are indicative of the presence of cancers in the human
body. Biomarkers may be produced by the cancer tissue itself or by other
cells in the body in response to cancer. They can be found in the
blood, stool, urine, tumor tissue, or other tissues or bodily fluids.
They enhance cancer detection and facilitate high-speed noninvasive
diagnosis using genomics and proteomics.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=202

North America dominated the market in 2016
North America
(comprising the US and Canada) is accounted for the largest share of
the global cancer biomarkers market in 2017, followed by Europe. The
large share of this geographic segment is mainly attributed to the
increasing government support for discovery and development of
biomarkers, increasing demand for personalized medicine, adoption of
advanced omics technologies for biomarker discovery, and rising use of
biomarkers in drug discovery and development by pharmaceutical
companies in that region.
The major players in the cancer
biomarkers profiling technology market are Abbott (US), Affymetrix
(US), Roche (Switzerland), Illumina (US), QIAGEN (Netherlands), Agilent
(US), Thermo Fisher (US), Merck (US), Becton Dickinson (US), and
Hologic (US).

Get Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=202

Polymerase Chain Reaction (PCR) is a laboratory technique used to make
multiple copies of a segment of DNA. It is very precise and can be used
to amplify or copy a specific DNA target from a mixture of DNA
molecules. It enables the detection of minimal residual disease and
also detects cancer with genetic abnormalities. PCR can help define
subgroups of patients that are suitable candidates for anti-cancer
therapies. PCR-based diagnostic kits are used to detect several
biomarkers such as B-Raf, Epidermal Growth Factor Receptor (EGFR), and
Kristen Rat Sarcoma (KRAS), among others, to access specific mutations
in clinical trial laboratories. They aid in selecting the right
candidates in clinical trials for treatment with tailored drugs.

Based on cancer type, the breast cancer segment accounted for the largest share of the market in 2016

The cancer biomarkers market on the basis of cancer type is classified
into breast, lung, colorectal, prostate, melanoma, leukemia, thyroid,
bladder, non-hodgkin’s lymphoma, kidney, and other cancers, such as
cervical, multiple myeloma, and CNS, gastric, liver, pancreatic, oral
cavity and pharynx, stomach, and ovarian cancers.

Next generation sequencing (NGS)

Sequencing is the process of determining the precise order of
nucleotides in a DNA/RNA sample. The advent of rapid sequencing methods
has greatly enhanced biological and medical research and the discovery
of biomarkers. Next-generation Sequencing (NGS) is one of the most
significant developments in genomics technologies with regards to cancer
biomarker discovery, diagnostics, and prognostics. It has advanced the
biomarker discovery process by accelerating the timeline of sequencing
as R&D efforts are no longer bound to a single gene or small gene
panels. Through massively parallel sequencing, this technology brings
about faster identification of genetic diseases in specific populations
or tissue types